ATE402697T1 - 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität - Google Patents

1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität

Info

Publication number
ATE402697T1
ATE402697T1 AT05707857T AT05707857T ATE402697T1 AT E402697 T1 ATE402697 T1 AT E402697T1 AT 05707857 T AT05707857 T AT 05707857T AT 05707857 T AT05707857 T AT 05707857T AT E402697 T1 ATE402697 T1 AT E402697T1
Authority
AT
Austria
Prior art keywords
trisubstituted
dihydro
antagonistic activity
pyrazole derivative
compounds
Prior art date
Application number
AT05707857T
Other languages
English (en)
Inventor
Josephus Lange
Cornelis Kruse
Stuivenberg Herman Van
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of ATE402697T1 publication Critical patent/ATE402697T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT05707857T 2004-01-30 2005-01-27 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität ATE402697T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53998304P 2004-01-30 2004-01-30
EP04100338 2004-01-30

Publications (1)

Publication Number Publication Date
ATE402697T1 true ATE402697T1 (de) 2008-08-15

Family

ID=34839806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05707857T ATE402697T1 (de) 2004-01-30 2005-01-27 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität

Country Status (20)

Country Link
EP (1) EP1713475B1 (de)
JP (1) JP4693787B2 (de)
KR (1) KR20060131861A (de)
CN (1) CN100563651C (de)
AT (1) ATE402697T1 (de)
AU (1) AU2005210163B2 (de)
BR (1) BRPI0507005A (de)
CA (1) CA2552940A1 (de)
DE (1) DE602005008555D1 (de)
DK (1) DK1713475T3 (de)
ES (1) ES2311972T3 (de)
HR (1) HRP20080549T3 (de)
IL (1) IL176547A (de)
MX (1) MXPA06008593A (de)
NO (1) NO20063866L (de)
PL (1) PL1713475T3 (de)
PT (1) PT1713475E (de)
RU (1) RU2360904C2 (de)
SI (1) SI1713475T1 (de)
WO (1) WO2005074920A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
ES2326461B1 (es) * 2005-07-15 2010-04-19 Laboratorios Del Dr. Esteve, S.A. Polimorfo de n-priperidinil-5-(4-clorofenil)-1-(2,4-dicloforenil)-4,5-dihidro-1h-pirazol-3-carboxamida y su uso como modulador de receptores de cannabinoides.
ES2330992B1 (es) * 2005-07-15 2010-07-06 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina heterociclilsustituidos, su preparacion y uso como medicamentos.
WO2007131538A1 (en) * 2005-07-15 2007-11-22 Laboratorios Del Dr. Esteve, S.A. Azepane- or azocane-substituted pyrazoline compounds, their preparation and use as medicaments
EP1910300A2 (de) 2005-07-15 2008-04-16 Laboratorios del Dr. Esteve S.A. Prodrugs von pyrazolinverbindungen, ihreherstellung und ihre verwendung als medikamente
EP1749820A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salze von substituierten Pyrazolin Derivaten, ihre Herstellung und Anwendung als Arzneimittel
EP1745783A1 (de) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazolinverbindungen, ihre Synthese und ihre Verwendung als Medikamente
EP1745781A1 (de) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Kombination von Cannabinoid Rezeptor Antagonist des Pyrazolin-Typs und Statin
ES2327379B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
EP1849776A1 (de) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepan- oder Azocan-substituierte Pyrazolinderivate, deren Herstellung und Anwendung als Arzneimittel
EP1749819A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. (rac)-N-piperidinyl-5-(4-chlorphenyl)-1(2,4-dichlorphenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid Hydraten
EP1743892A1 (de) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
ES2330993B1 (es) * 2005-07-15 2010-07-06 Laboratorios Del Dr. Esteve, S.A. Combinacion de antagonista del receptor de cannabinoides de tipo pirazolina y estatina.
EP1757588A1 (de) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Polymorph des N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamids und seine Verwendung als Cannabinoid-Rezeptor-Modulator
EP1743642A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Verwendung substituierter Pyrazolinverbindungen und ihrer Derivate zur Behandlung von Cannabinoidsystem-assoziierten Erkrankungen.
WO2007009682A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Oral pharmaceutical formulations comprising substituted pyrazoline compounds
ES2326952B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Hidratos de (rac) -n-piperidinil-5-(4-clorofenil)-1-(2,4-diclorofenil)4,5-dihidro-1h-pirazol-3-carboxamida.
WO2007009687A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Carbonyl substituted pyrazoline compounds, their preparation and use as cb1 receptor modulators
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
ES2348374B1 (es) * 2005-07-15 2011-08-02 Laboratorios Del Dr Esteve, S.A. Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos.
EP1743890A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
EP1743888A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Carbonyl-substituierte Pyrazolin-Verbindungen zur Verwendung als CB1-Rezeptor Modulatoren
EP1849784A1 (de) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indolin-substituierte Pyrazolinderivate, ihre Herstellung und Anwendung als Arzneimittel
EP1757589A1 (de) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Amorphe-Phase von einem substituierten Pyrazolin, deren Herstellung und Verwendung als Medikament
ES2326357B1 (es) * 2005-07-29 2010-04-21 Laboratorios Del Dr. Esteve, S.A. Fase amorfa de una pirazolina sustituida, su preparacion y su uso como medicamento.
EP1911747A1 (de) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamid-substituierte Pyrazolin-derivate, deren Herstellung sowie deren Verwendung als CB1 Modulatoren
ES2330071B1 (es) * 2007-01-15 2010-07-05 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas.
EP1944295A1 (de) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Nicht racemische Verbindungen von (R)-N-piperidinyl-5-(4-chlorophenyl)1-1(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid und (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid
ES2328653B1 (es) * 2007-01-15 2010-05-28 Laboratorios Del Dr. Esteve S.A. Combinacion de sustancias activas para el tratamiento de la diabetes.
EP1946778A1 (de) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Wirkstoffzusammensetzung für Diabetesbehandlung
EP1946777A1 (de) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazolinderivate zur Vermeidung von Gewichtszunahme
EP1946779A1 (de) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Zusammensetzung enthaltend substituierte Pyrazoline und gegen Dyslipämie wirksame Mittel
EP1947089A1 (de) * 2007-01-18 2008-07-23 Laboratorios del Dr. Esteve S.A. A-Polymorph eines substituierten Pyrazolins, seine Herstellung und Verwendung als Medikament
US8410135B2 (en) 2007-06-15 2013-04-02 Solvay Pharmaceuticals B.V. 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
EP2158184A2 (de) * 2007-06-15 2010-03-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-(1h)-pyrazol-derivate als cannabinoid-cb1-rezeptormodulatoren
EP2203427A2 (de) * 2007-09-20 2010-07-07 Abbott Healthcare Products B.V. 5-aryl-4,5-dihydro-(1h)-pyrazole als cannabinoid-cb1-rezeptoragonisten
EP2042175A1 (de) * 2007-09-21 2009-04-01 Laboratorios del Dr. Esteve S.A. Dosierungsschemata von CB1-Rezeptor-Liganden für die Behandlung von Fettleibigkeit
TW200948798A (en) * 2008-04-23 2009-12-01 Solvay Pharm Bv (5R)-1, 5-diaryl-4, 5-dihydro-1H-pyrazole-3-carboxamidine derivatives having CB1-antagonistic activity
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
IN2015DN03733A (de) 2012-11-13 2015-09-18 Us Health
WO2014208939A1 (en) * 2013-06-28 2014-12-31 Hanmi Pharm. Co., Ltd. 1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives as cannabinoid cb1 receptor antagonist, method for preparing same, and pharmaceutical composition comprising same
EP3140288B1 (de) * 2014-05-09 2023-01-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Pyrazol-derivate und deren verwendung als mediatoren des cannabinoid-rezeptors
CN115536649B (zh) * 2022-10-27 2024-12-20 成都中医药大学 一种多取代吡唑啉类化合物及其合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598633B2 (en) * 1987-01-05 1990-06-28 E.I. Du Pont De Nemours And Company 1-sub-phenyl-3-sub-phenylamino(thio) carbonyl-pyrazolines as insecticides
WO1992003421A2 (en) * 1990-08-17 1992-03-05 E.I. Du Pont De Nemours And Company Arthropodicidal pyrazolines, pyrazolidines and hydrazines
JPH07504658A (ja) * 1992-03-02 1995-05-25 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺節足動物性アミド類
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
UA74367C2 (uk) * 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ)
ATE284872T1 (de) * 2001-03-22 2005-01-15 Solvay Pharm Bv 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung
CN1529595A (zh) * 2001-09-21 2004-09-15 ������ҩ�����޹�˾ 具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物
AU2002333852B2 (en) * 2001-09-21 2006-07-13 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity

Also Published As

Publication number Publication date
NO20063866L (no) 2006-10-27
EP1713475A1 (de) 2006-10-25
MXPA06008593A (es) 2006-08-28
CN1913885A (zh) 2007-02-14
DE602005008555D1 (de) 2008-09-11
PL1713475T3 (pl) 2009-03-31
HK1099688A1 (en) 2007-08-24
SI1713475T1 (sl) 2008-12-31
BRPI0507005A (pt) 2007-06-05
IL176547A (en) 2010-06-30
AU2005210163B2 (en) 2010-05-13
RU2360904C2 (ru) 2009-07-10
EP1713475B1 (de) 2008-07-30
IL176547A0 (en) 2006-10-31
ES2311972T3 (es) 2009-02-16
CA2552940A1 (en) 2005-08-18
DK1713475T3 (da) 2008-12-01
JP2007519686A (ja) 2007-07-19
HRP20080549T3 (en) 2008-11-30
JP4693787B2 (ja) 2011-06-01
KR20060131861A (ko) 2006-12-20
WO2005074920A1 (en) 2005-08-18
RU2006131132A (ru) 2008-03-10
PT1713475E (pt) 2008-11-10
AU2005210163A1 (en) 2005-08-18
CN100563651C (zh) 2009-12-02

Similar Documents

Publication Publication Date Title
ATE402697T1 (de) 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
MXPA06013534A (es) Compuesto de cinamida.
MY148703A (en) Polycyclic cinnamide derivatives
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
DE602005007350D1 (de) Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TW200716135A (en) Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
GEP20125637B (en) Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
CY1117851T1 (el) Παραγωγα φαινυλ-πυρρολ-αμινογουανιδινης
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
WO2010056644A8 (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
ATE553095T1 (de) Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden
NO20070089L (no) DPP-IV inhibitorer
TNSN07006A1 (en) Novel heterocyclic compounds
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2008109027A3 (en) Tri-aryl/heteroaroaromatic cannabinoids and use thereof
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
DE502005008351D1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
UA84594C2 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists
NO20052197L (no) Fremgangsmate for fremstilling av pyrazol
EA201070381A1 (ru) 5-арил-4,5-дигидро-(1н)-пиразолы в качестве агонистов каннабиоидного сврецептора
MY145008A (en) 1-arylpyrazole derivatives as pesticidal agents
MX2007007554A (es) Oxiarenos sustituidos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1713475

Country of ref document: EP